Further to this, a recent study by Wang et al, demonstrated that individuals with colorectal adenomas expressing elevated COX-2 prior to treatment with celecoxib, a COX-2 inhibitor, were more likely to have fewer adenomas at follow-up surveillance compared to low COX-2-expressing adenoma patients [23]. This evidence concerns the gene PTGS2 and colorectal adenoma.